The correct prednisone starting dose in polymyalgia rheumatica is related to body weight but not to disease severity
© Cimmino et al; licensee BioMed Central Ltd. 2011
Received: 26 January 2011
Accepted: 14 May 2011
Published: 14 May 2011
the mainstay of treatment of polymyalgia rheumatica (PMR) is oral glucocorticoids, but randomized controlled trials of treatment are lacking. As a result, there is no evidence from controlled studies on the efficacy of different initial doses or glucocorticoid tapering. The aim of this study is to test if 12.5 mg prednisone/day is an adequate starting dose in PMR and to evaluate clinical predictors of drug response.
60 consecutive PMR patients were treated with a starting dose of 12,5 mg/day prednisone. Clinical, laboratory, and, in a subset of 25 patients, ultrasonographic features were recorded as possible predictors of response to prednisone. Remission was defined as disappearance of at least 75% of the signs and symptoms of PMR and normalization of ESR and CRP within the first month, a scenario allowing steroid tapering.
47/60 (78.3%) patients responded to 12.5 mg of prednisone after a mean interval of 6.6 ± 5.2 days. In univariate analysis, body weight and gender discriminated the two groups. In multivariate analysis, the only factor predicting a good response was low weight (p = 0.004); the higher response rate observed in women was explained by their lower weight. The mean prednisone dose per kg in the responders was 0.19 ± 0.03 mg in comparison with 0.16 ± 0.03 mg for non responders (p = 0.007).
12.5 mg prednisone is a sufficient starting dose in ¾ of PMR patients. The main factor driving response to prednisone in PMR was weight, a finding that could help in the clinical care of PMR patients and in designing prospective studies of treatment.
Keywordspolymyalgia rheumatica prednisone glucocorticoid ultrasonography
Polymyalgia rheumatica (PMR) is a common inflammatory condition affecting elderly people and involving the girdles . The mainstay of treatment is oral glucocorticoids (GC), with the recent BSR-BHPR guidelines suggesting an initial prednisone dose comprised between 15 and 20 mg as appropriate . However, probably because of the dramatic response of PMR to GC, randomized controlled trials of treatment are lacking. As a result, there is no evidence from controlled studies on the efficacy of different initial doses or drug tapering. The only controlled study suggests that initial prednisone doses ≤ 10 mg is associated with high incidence of recurrences, whereas doses ≥ 20 mg are associated with considerable side effects . Severe steroid toxicity is frequent, occurring in 65% of the patients, and is associated with duration of treatment and cumulative GC dosage . Up to 55% of PMR patients have relapsing disease and require long-term steroid treatment. In one descriptive study, the initial dose was linked to treatment duration and cumulative dosage, for low initial doses were associated with low subsequent maintenance doses . However, most studies are observational and their results could be biased by confounding by indication, i.e. more severe patients being likely to receive higher doses of GC. Identifying the correct starting dose of prednisone for PMR patients could contribute to avoid overtreatment and to reduce the occurrence of side effects.
The aims of this study are (a) to test if 12.5 mg prednisone daily is an adequate starting dose in PMR and (b) to evaluate the factors that could predict a positive response to this initial dose.
Sixty consecutive patients with PMR, diagnosed according to the criteria of Bird et al.  and visited in two rheumatological tertiary referral centers (Universities of Genova and Pavia, Italy), were considered. Enrolment lasted one year and follow-up lasted one month. An informal chart review was done after 6 month from enrolment to assess the rate of exacerbations. There were 25 men and 35 women; mean age was 71.4 ± 7.2 years. The study protocol was approved by the relevant ethical committees. After written informed consent was obtained, the following demographic and disease characteristics were evaluated: age, sex, body weight measured at the time of the first visit, duration of disease, presence of fatigue, fever, and weight loss, duration of morning stiffness, presence of carpal tunnel syndrome, RS3PE, peripheral arthritis or tenosynovitis. Standardized clinical examination included the following: a) tenderness on palpation of bicipital tendon root, coracoid, lesser and greater tuberosities, and posterior cuff; b) pain worsened by passive and active mobilization, and limitation of motion of the shoulder; c) pain in the groin worsened by passive and active movements and associated with positive Fabere's test, suggesting coxofemoral synovitis; d) aching on the lateral aspect of the hip and thigh, increased by external rotation and abduction and localized tenderness on palpation over the greater trochanter, suggesting trochanteric bursitis; e) tenderness aggravated by extension and relieved by flexion of the hip, suggesting ileo-psoas bursitis; f) pain over the ischions aggravated by sitting and lying, associated with tenderness on palpation over the ischial tuberosities, suggesting ischio-gluteal bursitis; g) paravertebral tenderness and limitation of movement in the lumbar and cervical spine. The two clinical assessors involved in the study (MAC and RC) participated in two training sessions to standardize clinical examination. Patients were instructed to subjectively rate the intensity of fatigue and of the pain experienced during the visit on a scale between 0 and 10. Laboratory and imaging investigations included erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), IgM rheumatoid factor (RF) and ultrasonography (US) of the shoulders. This last examination was performed only in a subset of 25 patients. It included the evaluation of gleno-humeral synovitis (hypoechoic or anechoic effusion larger than 2 mm when measured with a posterior approach and arm in external rotation, or larger than 3.8 mm when measured in the axillary recess between bone and capsule), long head biceps tenosynovitis (hypoechoic or anechoic effusion of the tendon's sheath with diameter larger than 1.4 mm), and subacromial/subdeltoid bursitis (hypoechoic or anechoic effusion with largest sagittal diameter larger than 2 mm). All examinations were performed at the time of the first visit; clinical examination and parameters of inflammation were evaluated also at 1 and 4 weeks. All the patients were treated with 12.5 mg of prednisone daily in the early morning. For the purpose of the study, patients with clinical and laboratory remission of PMR with the above reported dose of prednisone, were considered responders. Remission was defined as at least a 70% global improvement of the signs and symptoms of PMR and normalization of ESR and CRP within the first month, allowing steroid tapering. Non-responders were patients who did not reach remission and, as a consequence, needed an increase in prednisone dosage in the first month of treatment. The interval between treatment initiation and response to it was recorded. The patients were instructed to record on a diary their clinical status and the exact day in which remission was achieved.
Means were compared by the Student's t test or by one way analysis of variance if their distribution was normal and by the Kruskall Wallis test when it was non parametrical. Frequencies were compared by Fischer's exact test. Changes in ESR and CRP during the study period were evaluated between subjects and within subjects by repeated measures ANOVA. A multiple regression model was also used with response to treatment as dependent variable. All the calculations were performed using Medcalc® version 188.8.131.52 (Belgium) as statistical software.
Comparison of demographic, clinical, and laboratory results in PMR patients with or without response to 12.5 mg daily of prednisone
71.3 ± 7.1
71.5 ± 7.9
67.4 ± 11.4
78.5 ± 13.9
Disease duration (days)
Morning stiffness (minutes)
100.7 ± 85.9
89.0 ± 52.2
Carpal tunnel syndrome
63.8 ± 25.8
62.5 ± 22.4
Of the 13 non-responders, 7 still had PMR signs and symptoms, 5 has elevated ESR, and 3 elevated CRP, with only one patient showing both elevated CRP and ESR. Their dose of prednisone had been increased within one month from initiation of therapy between 2.5 and 12.5 mg/day with a resulting mean dose of 21.1 ± 3.2 mg/day. In this group, remission was reached after a mean interval of 41.2 ± 21.8 days. After dose adjustment, their mean prednisone dose per kg was 0.27 ± 0.06 mg. The median dose per kg for the whole group was 0.20 mg (range 0.13 mg-0.37 mg; 95% CI 0.19 mg-0.21 mg).
At the informal chart review performed at 6 months from study initiation, 14/60 (23.3%) of the patients had had one or more exacerbations. They occurred in 8/47 (17%) responders and in 4/13 (30.8%) non-responders (p = 0.48).
Our results support the hypothesis that a low initial dose of prednisone is sufficient to control PMR in the majority of patients. They also suggest that 0.20 mg per kg weight could be the adequate starting dose, although these data should be confirmed in prospective studies in which steroid dose is adjusted to body weight. It is possible that, due to the open design of the study, a placebo effect increased the response rate of our patients. However, since no comparison was made between different treatments, we think it could not have biased the results. Responders reached clinical remission in 6.6 days in average; most of them within 10 days from onset of therapy. This observation suggests that a close follow-up in the first days after diagnosis and treatment initiation is important to ensure that the patient is administered an adequate prednisone dosage.
There is only one comparison of two different dosages of GC in the literature : PMR patients were randomly assigned to an initial regimen of 10 mg or 20 mg prednisolone and followed for two months. The patients on the low dose GC regimen had a higher incidence of relapses during the follow-up. The same incidence of giant cell arteritis was seen in both groups. No attempt was made to correlate efficacy with body weight in this study. Conversely, an initial prednisolone dose of 10 mg/day was felt adequate by Behn et al. , with only 8/67 (11.9%) PMR patients needing an increase in dosage. Another study used a standardized schedule of prednisone with a starting dose of 20 mg/day . Twenty out of 27 patients (74%) reached remission with this regimen, a percentage similar to that obtained in our study with a much lower dose. This observation suggested that there is a subset of a quarter of PMR patients with steroid-resistant disease , regardless of the initial GC dose utilized. Other observational studies used initial GC mean doses comprised between 12.8 mg  and 22.8 mg . However, due to lack of clinical information, it is impossible to derive from these papers how effective was GC in the initial period of treatment.
Disease activity, evaluated by clinical, laboratory, and ultrasonographic parameters, was not important to predict response to therapy. However, the power to test the predictive value of US was probably low because of the limited number of patients in whom the examination was performed. In univariate analysis, women showed a slightly better response to treatment than men. In contrast, previous data on PMR  and rheumatoid arthritis  have reported higher disease severity and lower rate of response to GC in women. In fact, when multivariate analysis was performed on our cases, the association of female sex to response appeared spurious, being related to the lower mean weight of women. The observation that the optimal starting dose depends on weight and not on disease activity, and is relatively low, may confirm the view that GC action in PMR is more of replacement type than anti-inflammatory . The importance of body weight in the response to prednisone treatment is not surprising, in view of the fact that GC have a high volume of distribution and are highly lypophilic .
One of the limitations of this study is that clinical assessors could not be blinded to patient's weight. In addition, the design of the study limited the follow up to only one month. To partially overcome this last limitation, we performed an informal chart review to assess the presence of exacerbations within the first 6 months of treatment. Only 23% of the patients had one or more exacerbations with no differences between initial responders and non-responders. As a result, the rate of exacerbations was low in comparison with other studies using similar  or higher initial doses of GC [9, 11] and response to a lower initial dose of prednisone was not correlated with a higher incidence of exacerbations. Although we cannot assume that a low GC starting dose necessarily corresponds to a low cumulative dosage, this is suggested by several observational studies .
Response to GC is one of the classification criteria for PMR in most studies , but the dose at which the drug should be administered to the effect has not been defined. An international group has recently addressed this problem by consensus, with rapid response to steroids defined as > 75% global response within 1 week to 15-20 mg daily of prednisone . The BSR-BHPR guidelines suggest the same , but there is only type C evidence to support this view . Our data could help standardize the optimal starting dose. They suggest that, in low-weight patients, this dose could be lower than that previously suggested. In fact 78.3% of our patients could benefit from a starting dose below 15 mg prednisone. This is in keeping with the EULAR recommendations to use the lowest possible GC dose in PMR . The mean time interval needed to reach remission in our cohort of responsive patients was similar to that suggested by the panel of experts.
In conclusion, in our experience low dose GC was effective in the majority of PMR patients and the main factor driving response to steroids in PMR was weight, a finding that could help to manage the clinical care of PMR patients and design prospective studies of treatment.
List of Abbreviations
Remitting seronegative symmetric synovitis with pitting edema
Erythrocyte sedimentation rate
IgM rheumatoid factor
This work was supported in part by a grant from the University of Genova (Fondi di Ateneo).
- Salvarani C, Cantini F, Boiardi L, Hunder GG: Polymyalgia rheumatica and giant-cell arteritis. N Engl J Med. 2002, 347: 261-271. 10.1056/NEJMra011913.View ArticlePubMedGoogle Scholar
- Dasgupta B, Borg FA, Hassan N, Barraclough K, Bourke B, Fulcher J, Hollywood J, Hutchings A, Kyle V, Nott J, Power M, Samanta A: BSR and BHPR guidelines for the management of polymyalgia rheumatica. Rheumatology (Oxford). 2010, 49: 186-90. 10.1093/rheumatology/kep303a.View ArticleGoogle Scholar
- Kyle V, Hazleman BL: Treatment of polymyalgia rheumatic and giant cell arteritis. II. Relation between steroid dosing and steroid associated side effects. Ann Rheum Dis. 1989, 48: 662-6. 10.1136/ard.48.8.662.View ArticlePubMedPubMed CentralGoogle Scholar
- Gabriel SE, Sunku J, Salvarani C, O'Fallon WM, Hunder GG: Adverse outcomes of anti-inflammatory therapy among patients with polymyalgia rheumatica. Arthritis Rheum. 1997, 40: 1873-8. 10.1002/art.1780401022.View ArticlePubMedGoogle Scholar
- Myklebust G, Gran JT: Prednisolone maintenance dose in relation to starting dose in the treatment of polymyalgia rheumatica and temporal arteritis. A prospective two-year study in 273 patients. Scand J Rheumatol. 2001, 30: 260-7. 10.1080/030097401753180327.View ArticlePubMedGoogle Scholar
- Bird HA, Esselinckx W, Dixon AS, Mowat AG, Wood PH: An evaluation of criteria for polymyalgia rheumatica. Ann Rheum Dis. 1979, 38: 434-439. 10.1136/ard.38.5.434.View ArticlePubMedPubMed CentralGoogle Scholar
- Kyle V, Hazleman BL: Treatment of polymyalgia rheumatic and giant cell arteritis. I. Steroid regimens in the first two months. Ann Rheum Dis. 1989, 48: 658-661. 10.1136/ard.48.8.658.View ArticlePubMedPubMed CentralGoogle Scholar
- Behn AR, Perera T, Myles AB: Polymyalgia rheumatica and corticosteroids: how much for how long?. Ann Rheum Dis. 1983, 42: 374-8. 10.1136/ard.42.4.374.View ArticlePubMedPubMed CentralGoogle Scholar
- Weyand CM, Fullbright JW, Evans JM, Hunder GG, Goronzy JJ: Corticosteroid requirements in polymyalgia rheumatica. Arch Intern Med. 1999, 159: 577-84. 10.1001/archinte.159.6.577.View ArticlePubMedGoogle Scholar
- Narvàez J, Nolla-Solé JM, Clavaguera MT, Valverde-García Roig-Escofet D: Longterm therapy in polymyalgia rheumatica: effect of coexistent temporal arteritis. J Rheumatol. 1999, 26: 1945-52.PubMedGoogle Scholar
- Ayoub WT, Franklin CM, Torretti D: Polymyalgia rheumatica. Duration of therapy and long-term outcome. Am J Med. 1985, 79: 309-15. 10.1016/0002-9343(85)90309-2.View ArticlePubMedGoogle Scholar
- Cimmino MA, Parodi M, Caporali R, Montecucco C: Is the course of steroid-treated polymyalgia reumatica more severe in women?. Ann N Y Acad Sci. 2006, 1069: 315-21. 10.1196/annals.1351.030.View ArticlePubMedGoogle Scholar
- Sokka T, Toloza S, Cutolo M, Kautiainen H, Makinen H, Gogus F, Skakic V, Badsha H, Peets T, Baranauskaite A, Géher P, Ujfalussy I, Skopouli FN, Mavrommati M, Alten R, Pohl C, Sibilia J, Stancati A, Salaffi F, Romanowski W, Zarowny-Wierzbinska D, Henrohn D, Bresnihan B, Minnock P, Knudsen LS, Jacobs JW, Calvo-Alen J, Lazovskis J, Pinheiro Gda R, Karateev D, et al.: Women, men, and rheumatoid arthritis: analyses of disease activity, disease characteristics, and treatments in the QUEST-RA study. Arthritis Res Ther. 2009, 11: R7-Epub 2009 Jan 14PubMedPubMed CentralGoogle Scholar
- Straub RH, Cutolo M: Further evidence for insufficient hypothalamic-pituitary-glandular axes in polymyalgia rheumatica. J Rheumatol. 2006, 33: 1219-23.PubMedGoogle Scholar
- Miller WL, Chrousos GP: The adrenal cortex. Endocrinology and metabolism. Edited by: Felig P, Frohman LA. 2001, McGraw Hill, 385-524.Google Scholar
- Cimmino MA, Salvarani C: Polymyalgia rheumatica and giant cell arteritis. Baillière's Clin Rheumatol. 1995, 9: 515-27.View ArticleGoogle Scholar
- Dasgupta B, Salvarani C, Schirmer M, Crowson CS, Maradit-Kremers H, Hutchings A, Matteson EL, American College of Reumatology Work Group for Development of Classification Criteria for PMR: Developing classification criteria for polymyalgia reumatica: comparison of views from an expert panel and a wider survey. J Rheumatol. 2008, 35: 270-7.PubMedGoogle Scholar
- Ntatsaki E, Watts RA: Management of polymyalgia rheumatica. New guidelines are a step forward, but may unanswered questions remain. Br Med J. 2010, 340: c620-10.1136/bmj.c620.View ArticleGoogle Scholar
- Hoes JN, Jacobs JW, Boers M, Boumpas D, Buttgereit F, Caeyers N, Choy EH, Cutolo M, Da Silva JA, Esselens G, Guillevin L, Hafstrom I, Kirwan JR, Rovensky J, Russell A, Saag KG, Svensson B, Westhovens R, Zeidler H, Bijlsma JW: EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis. 2007, 66: 1560-7. 10.1136/ard.2007.072157.View ArticlePubMedPubMed CentralGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2474/12/94/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.